Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891587599> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2891587599 abstract "Abstract Background For patients with stage II/III esophageal squamous cell carcinoma (ESCC), neoadjuvant chemotherapy with cisplatin and 5-fluorouracil followed by surgery has been regarded as a standard treatment in Japan based on the result of Japan Clinical Oncology Group trial (JCOG9907). However, the survival outcome of this doublet chemotherapy has been still unsatisfactory especially in stage III patients. Triplet-regimen, consisting of docetaxel plus cisplatin and 5-fluorouracil (DCF), showed good responses and survivals in some previous phase II studies, and therefore neoadjuvant DCF seems promising for more advanced stage. We adopted neoadjuvant DCF chemotherapy for patients with advanced ESCC. Methods We retrospectively analyzed 48 patients with ESCC treated with DCF as neoadjuvant chemotherapy from January 2013 to October 2017 in our hospital. All patients were in clinical T3–4a/N1–2/M0 or T1b-2 with bulky lymph metastasis based on the TNM classification 7th edition. DCF regimen consisted of i.v. docetaxel (60–70 mg/m2) on day 1 and cisplatin (60–70 mg/m2) on day 1, and continuous infusion of fluorouracil (600–700 mg/m2) on days 1–5. This regimen was repeated every 4 weeks. Results Forty-six patients (96%) completed 2 cycles of DCF. According to revised RECIST guideline, response rate was 29% (CR, 2; PR, 12; SD, 14; PD, 8; Non-CR/non-PD, 12). Forty-two patients except PD underwent surgery; R0 resection was achieved in 40 patients. Among 34 patients observed for more than 1 year after initial treatment, 1 year survival rate and overall survival time were 72.7% [95%CI: 49.1–86.7] and 20.1 months [95%CI: 9.4–30.6] in SD, Non-CR/non-PD and PD patients, while no patients died at the 1 year and did not reach median survival in CR and PR group (P = 0.001). Conclusion Survival of advanced ESCC patients was strongly associated with the clinical response to neoadjuvant DCF. It might be an indicator to select good candidates for surgical therapy. Disclosure All authors have declared no conflicts of interest." @default.
- W2891587599 created "2018-09-27" @default.
- W2891587599 creator A5005090790 @default.
- W2891587599 creator A5008518040 @default.
- W2891587599 creator A5015745313 @default.
- W2891587599 creator A5022531581 @default.
- W2891587599 creator A5025499666 @default.
- W2891587599 creator A5028898783 @default.
- W2891587599 creator A5062350669 @default.
- W2891587599 creator A5064274388 @default.
- W2891587599 creator A5075433404 @default.
- W2891587599 creator A5089096604 @default.
- W2891587599 date "2018-09-01" @default.
- W2891587599 modified "2023-10-03" @default.
- W2891587599 title "PS02.100: ASSOCIATION BETWEEN RESPONSES OF NEOADJUVANT DOCETAXEL PLUS CISPLATIN AND FLUOROURACIL (DCF) CHEMOTHERAPY AND SURVIVALS IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA PATIENTS" @default.
- W2891587599 doi "https://doi.org/10.1093/dote/doy089.ps02.100" @default.
- W2891587599 hasPublicationYear "2018" @default.
- W2891587599 type Work @default.
- W2891587599 sameAs 2891587599 @default.
- W2891587599 citedByCount "0" @default.
- W2891587599 crossrefType "journal-article" @default.
- W2891587599 hasAuthorship W2891587599A5005090790 @default.
- W2891587599 hasAuthorship W2891587599A5008518040 @default.
- W2891587599 hasAuthorship W2891587599A5015745313 @default.
- W2891587599 hasAuthorship W2891587599A5022531581 @default.
- W2891587599 hasAuthorship W2891587599A5025499666 @default.
- W2891587599 hasAuthorship W2891587599A5028898783 @default.
- W2891587599 hasAuthorship W2891587599A5062350669 @default.
- W2891587599 hasAuthorship W2891587599A5064274388 @default.
- W2891587599 hasAuthorship W2891587599A5075433404 @default.
- W2891587599 hasAuthorship W2891587599A5089096604 @default.
- W2891587599 hasConcept C121608353 @default.
- W2891587599 hasConcept C126322002 @default.
- W2891587599 hasConcept C141071460 @default.
- W2891587599 hasConcept C143998085 @default.
- W2891587599 hasConcept C146357865 @default.
- W2891587599 hasConcept C151730666 @default.
- W2891587599 hasConcept C2776694085 @default.
- W2891587599 hasConcept C2778239845 @default.
- W2891587599 hasConcept C2778292576 @default.
- W2891587599 hasConcept C2780456651 @default.
- W2891587599 hasConcept C2781190966 @default.
- W2891587599 hasConcept C2781413609 @default.
- W2891587599 hasConcept C530470458 @default.
- W2891587599 hasConcept C71924100 @default.
- W2891587599 hasConcept C86803240 @default.
- W2891587599 hasConcept C90924648 @default.
- W2891587599 hasConceptScore W2891587599C121608353 @default.
- W2891587599 hasConceptScore W2891587599C126322002 @default.
- W2891587599 hasConceptScore W2891587599C141071460 @default.
- W2891587599 hasConceptScore W2891587599C143998085 @default.
- W2891587599 hasConceptScore W2891587599C146357865 @default.
- W2891587599 hasConceptScore W2891587599C151730666 @default.
- W2891587599 hasConceptScore W2891587599C2776694085 @default.
- W2891587599 hasConceptScore W2891587599C2778239845 @default.
- W2891587599 hasConceptScore W2891587599C2778292576 @default.
- W2891587599 hasConceptScore W2891587599C2780456651 @default.
- W2891587599 hasConceptScore W2891587599C2781190966 @default.
- W2891587599 hasConceptScore W2891587599C2781413609 @default.
- W2891587599 hasConceptScore W2891587599C530470458 @default.
- W2891587599 hasConceptScore W2891587599C71924100 @default.
- W2891587599 hasConceptScore W2891587599C86803240 @default.
- W2891587599 hasConceptScore W2891587599C90924648 @default.
- W2891587599 hasLocation W28915875991 @default.
- W2891587599 hasOpenAccess W2891587599 @default.
- W2891587599 hasPrimaryLocation W28915875991 @default.
- W2891587599 hasRelatedWork W1963662298 @default.
- W2891587599 hasRelatedWork W1990897966 @default.
- W2891587599 hasRelatedWork W1994624462 @default.
- W2891587599 hasRelatedWork W2010389831 @default.
- W2891587599 hasRelatedWork W2084414488 @default.
- W2891587599 hasRelatedWork W2469261890 @default.
- W2891587599 hasRelatedWork W2735933086 @default.
- W2891587599 hasRelatedWork W2891587599 @default.
- W2891587599 hasRelatedWork W3111826816 @default.
- W2891587599 hasRelatedWork W4237179769 @default.
- W2891587599 isParatext "false" @default.
- W2891587599 isRetracted "false" @default.
- W2891587599 magId "2891587599" @default.
- W2891587599 workType "article" @default.